Navigation Links
Sangamo Announces Pricing of Public Offering of Common Stock
Date:10/7/2009

RICHMOND, Calif., Oct. 7 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced the pricing of a public offering of 3,000,000 shares of its common stock. The offering is expected to close on or about October 13, 2009, subject to the satisfaction of customary closing conditions. In addition, Sangamo has granted the underwriter a 30-day option to purchase up to an additional 450,000 shares of common stock to cover over-allotments, if any.

Jefferies & Company, Inc. is acting as sole book-running manager in this offering.

A registration statement relating to the shares of common stock issued in the offering has been filed with, and declared effective by, the Securities and Exchange Commission (the "SEC")." A prospectus supplement relating to the offering will be filed with the SEC. Copies of the prospectus supplement relating to this offering, when available, may be obtained from Jefferies & Company, Inc., Attention: Syndicate Prospectus Department, 520 Madison Avenue, New York, NY, 10022 or at (888) 449-2342. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic((TM)) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy and ALS. Sangamo also has two Phase 1 clinical trials to evaluate safety an
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sigma-Aldrich(R) and Sangamo BioSciences Announce Major Expansion of ZFP Technology License Agreement
2. Sangamo BioSciences Announces Presentation at the UBS Global Life Sciences Conference
3. Sangamos Zinc Finger Nuclease Technology Used to Efficiently Modify Human Stem Cells
4. Sangamo BioSciences Reports Second Quarter 2009 Financial Results
5. Sangamo BioSciences Announces Second Quarter 2009 Conference Call and Webcast
6. Sangamo BioSciences Announces Presentation at the Needham Life Sciences Conference
7. Sangamo BioSciences Receives $100,000 Grand Challenges Explorations Grant for Innovative Global Health Research
8. Sangamo BioSciences Announces Publication in Nature of the Use of Zinc Finger Nucleases to Accelerate Precision Trait Stacking in Commercial Crop Species
9. Sangamo BioSciences Announces First Quarter 2009 Conference Call and Webcast
10. Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results
11. Sangamo BioSciences Initiates Phase 1 Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... ... June 30, 2015 , ... Smarter ... — a revolutionary new archwire that allows orthodontists to simultaneously apply different forces ... the efficacy of SmartArch. “We’re thrilled about taking SmartArch one step closer to ...
(Date:6/29/2015)... ... 2015 , ... The global microfluidics market is expected to ... to 2020). The market is mainly driven by the rising geriatric population, growing ... lack of adequate healthcare and research infrastructure in emerging markets, dearth of skilled ...
(Date:6/29/2015)... According to a new market research report "Aptamers Market ... by Technology (SELEX, Other Technologies), by End Users (Academic Research ... 2020", published by MarketsandMarkets, the global Aptamers Market is expected ... 2015, at a CAGR of 17.89%. Browse ... igures spread through 125 P ages ...
(Date:6/26/2015)... MILFORD, Mass. , June 26, 2015 /PRNewswire/ ... in vitro diagnostics manufacturers, today announced that it ... (CRADA) with the National Cancer Institute (NCI), part ... reference materials and positive controls for cancer assays. ... to mix and accurately quantitate control DNA biosynthetics ...
Breaking Biology Technology:New case studies for SmartArch orthodontic archwire paves way to product launch later this year 2Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 2Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 3Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 4Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 5Aptamers Market Worth $244.93 Million by 2020 2Aptamers Market Worth $244.93 Million by 2020 3Aptamers Market Worth $244.93 Million by 2020 4SeraCare Life Sciences Signs CRADA with NCI to Advance Cancer Diagnostics 2SeraCare Life Sciences Signs CRADA with NCI to Advance Cancer Diagnostics 3
... Pharma,Inc. (Nasdaq: APPY ) an emerging bio-pharmaceutical ... diagnostics for animals and humans, today,announced that it ... a private placement with a group of existing ... AspenBio will receive,approximately $18 million in gross proceeds ...
... N.J., Dec. 20 Memory,Pharmaceuticals Corp. (Nasdaq: ... in a randomized, double-blind, placebo-controlled Phase 2a clinical,trial ... receptor partial,agonist, in cognitive impairment associated with schizophrenia ... tolerability and cognitive effects,of three doses of MEM ...
... /Xinhua-PRNewswire-FirstCall/ --,China-Biotics, Inc. (OTC Bulletin Board: CHBT), a ... marketing and,distribution of probiotics dietary supplements, today announced ... Eastern Time on Monday, August 13,2007, to discuss ... June 30, of its 2008 fiscal year. ...
Cached Biology Technology:AspenBio Pharma Announces $18 Million Private Placement of Common Stock 2AspenBio Pharma Announces $18 Million Private Placement of Common Stock 3Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia 2Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia 3Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia 4China-Biotics, Inc. Announces Conference Call to Discuss First Quarter FY 2008 Results 2
(Date:6/23/2015)... June 23, 2015   MedNet Solutions , ... the entire spectrum of clinical research, is pleased ... ™ , the company,s intuitive, flexible and affordable ... Silver 2015 Stevie® Award by the American ... Services Website category.  The American Business Awards are ...
(Date:6/23/2015)... PALM BEACH GARDENS, Fla. , June ... of multi-factor identity management and authentication solutions, today ... Altus strong, multi-factor authentication solution.  The ... ease of use of the DigitalPersona Altus ... and biometric reader compatibility. In ...
(Date:6/17/2015)... , Deutschland und GERMANTOWN, Maryland ... Investigator ®   Produktlinie mit DNA-Tests ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt Prime Standard: ... neue STR-Testkits der Produktlinie Investigator ... in den Markt eingeführt. Die neuen Kits zur Erstellung ...
Breaking Biology News(10 mins):MedNet Solutions' iMedNet eClinical Wins Silver Stevie Award 2Crossmatch Releases Enhanced DigitalPersona Altus Advanced Authentication Functionality 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 3QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 4QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 5QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 6
... in the brains of rats to help focus ... sensory pathways to make it easier to block ... found. , Their report in the Journal of ... with attention deficit and hyperactivity disorders to improve ...
... unique nanoparticles that convert laser light into useful information, ... pH meter. , The discovery, which appears online this ... the first potential means of measuring accurate pH changes ... tissue and cells. , "Almost every biologist I speak ...
... PLoS Genetics has published the findings of a team ... Institute that provides a whole genome analysis of the ... as Dictyostelium. , Led by Dr. Janet ... of kinases, which are enzymes involved in cell communication ...
Cached Biology News:Ritalin packs punch by elevating norepinephrine, suppressing nerve signal transmissions 2Ritalin packs punch by elevating norepinephrine, suppressing nerve signal transmissions 3Rice scientists make first nanoscale pH meter 2Scientists elucidate the kinome of key model organism 2